JT 109
Alternative Names: JT-109Latest Information Update: 13 Jan 2023
Price :
$50 *
At a glance
- Originator Institute of Microbiology of the Chinese Academy of Sciences; Shanghai Junshi Biosciences
- Developer Shanghai Junshi Biosciences
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Zika virus infection
Most Recent Events
- 13 Jan 2023 Preclinical trials in Zika virus infection in China (Parenteral) before January 2023 (Shanghai Junshi Biosciences pipeline, January 2023)
- 01 Oct 2021 Junshi Biology (Shanghai Junshi Biosciences) and the Institute of Microbiology of the Chinese Academy of Sciences signs a cooperation agreement to jointly develop a Zika virus vaccine